SUMMARY
Suxamethonium is known as an agonistic neuromuscular blocker, with the ability to produce a rapid and profound loss of muscle tone. Myotonia of the jaw muscles of a marked degree (termed masseter spasm (MS), masseteric muscle spasm (MMS)j masseteric muscle rigidity (MMR) or trismus), is recognized as a potential herald for malignant hyperthermia (MH) [1, 2] .
Retrospective studies of patients presenting with this feature suggest that about 50 % prove to be susceptible to malignant hyperthermia (MHS) [3] . Therefore 50% of referrals with MMS are apparently normal (MHN), although a few show EMG changes consistent with myotonia and so may have one of the myotonic muscle diseases, such as myotonia congenita.
More recently, there have been two studies reporting increasing jaw stiffness with resistance to mouth opening following i.v. suxamethonium [4, 5] . Different populations (children or adults), different induction techniques (inhalation or i.v.) and different methods of measurement prevent direct comparison, but both of these studies indicate that an increase in the tone of the jaw muscles may be a normal response following suxamethonium. This study presents the results of an investigation into the incidence and degree of change in jaw tone following different doses of suxamethonium in adults after induction of anaesthesia with thiopentone.
PATIENTS AND METHODS
We studied 50 healthy adult patients (ASA I and II) presenting for elective surgery for which general anaesthesia with intubation was appropriate; the study was approved by the local District Ethics Committee. Weight, sex and age of the patients were recorded.
All patients were premedicated with diazepam 10 mg at least 90 min before induction of anaesthesia. Following preoxygenation, a sleep dose of thiopentone was administered i.v. via an indwelling winged needle in the dorsum of the left hand and anaesthesia maintained thereafter with 66% nitrous oxide in oxygen. Additional small increments of thiopentone were given, if the level of anaesthesia became too light as judged by clinical parameters. The 50 patients were allocated to five groups of 10 patients, each receiving a different dose of suxamethonium diluted to a volume of 5 ml with 0.9 % saline: 0.25 mg kg" Muscle twitch. Supramaximal stimulation of the ulnar nerve at the elbow using a Bard Biomedical 750 digital transcutaneous peripheral nerve stimulator (square wave of 0.2 s duration at 1 Hz) was used and thumb adduction recorded using a manometer.
Fasciculation. Onset and offset of fasciculations in the jaw, tongue muscles, or both were assessed clinically and recorded using a remote incident marker. Figure 2 is a diagrammatic representation of the study. Time zero was taken as the end-point of the suxamethonium injection. Measurements included the onset and offset times for fasciculations, the offset time for twitch, the onset, peak and offset times for increase in tone, and the magnitude of the tone change at its peak and at the onset and offset of fasciculations and at 5 and 10 s after each event. The area under the tone curve was calculated.
Laryngoscopy was not attempted until all jaw tone changes had returned to initial resting values.
Demographic data were analysed using a oneway analysis of variance for independent samples. Similarly, the duration of suxamethonium injection and the preload applied were compared between the five groups using one-way analysis of variance for independent samples. Regression analysis was used to compare the five suxamethonium dose groups, with respect to fasciculation onset, offset and duration times; twitch offset time; increased tone onset, offset, peak and duration times; maximum tone; area under curve of tone increase; tone occurring at onset and offset of fasciculation and 5 and 10 s after each event.
Significance was assessed by Student's t test.
RESULTS
There were no significant differences between the five groups with respect to age and weight (table  I) , or duration of injection of suxamethonium and preload (table II) . There were significant negative correlations BRITISH JOURNAL OF ANAESTHESIA between suxamethonium dose and time of onset of fasciculations, the latter decreasing from 14.7 (SD 7.7) s with group A to 8.1 (2.9) s with group E (P < 0.01). Likewise there was a significant negative correlation between dose and offset of fasciculations, the latter decreasing from 38.7 (14. (table III) .
The timing of the onset of the increase in jaw tone showed a significant negative correlation with dose of suxamethonium, occurring at 23.3 (13.7) s for group A, but diminishing to 11.2 (4.6) s for group E (P < 0.01). Similar significant negative correlations occurred with respect to time of offset 70.4 (17.6) s for group A decreasing to 37.1 (14.7) s for group E (P < 0.01), duration of positive tone 50.7 (16.2) s for group A decreasing to 25.9 (13.1) s for group E (P < 0.01), and timing of peak tone 53.0 (15.0) s for group A decreasing to 19.6 (5.5) s for group E (P < 0.01) (table IV). No significant correlation was found between dose of suxamethonium and the magnitude of the increases in jaw tone (442 (356) g for group A and 457 (501) g for group E), or the calculated area under the tone curve (11.4 (11.7) g s for group A and 4.6 (5.3) g s for group E) (table V). Similarly, there were no significant correlations between dose and the tone generated at the three set times related to each of fasciculation onset and offset (table VI) . However, in all dose groups approximately 50% of patients were still generating increased tone 10 s after the offset of fasciculation ( fig. 3) . Figure 4 illustrates the distribution of peak tone values in each of the five groups.
Laryngoscopy was attempted at 60-90 s after the end of suxamethonium injection in all patients. In those requiring repeat suxamethonium, the final laryngoscopy occurred within 3 min of the end of the initial injection of suxamethonium. Six patients in group A and one each in groups B and C required additional suxamethonium for intubation. In the lower dose groups, this was presumed to be a result of inadequate paralysis, whilst in the one patient in group C no change in jaw tone from resting values was detected, but mouth opening proved impossible. Intubation was successful following the second dose of suxamethonium. 
DISCUSSION
Suxamethonium was first used in humans in 1951 [6, 7] . It is surprising that the observation that this drug has myotonic properties has been so delayed, especially as generations of anaesthetists have used suxamethonium as an important part of the rapid induction sequence. In the knowledge of the results of this study, it is tempting to suggest that intubation is achieved in these circumstances under the influence of thiopentone and before the suxamethonium-induced masseteric spasm has occurred. Delayed intubation resulting from inexperience could result in worsening conditions until the masseteric spasm has worn off and tone returned to baseline after about 60-90 s. The best time for intubation, provided suxamethonium 0.7-1.0 mg kg" 1 is given, is 20-30 s after cessation of facial fasciculations.
From this study it would appear that the increase in masseter muscle tone after suxamethonium is distributed normally. It can be predicted from the standard deviation statistics that one patient in every 20 may show a masseteric muscle tone increase of greater than 1500 g, and one patient in every 100 may show an increase greater than 2000 g. Some of the patients with the greatest change would, in certain circumstances, be interpreted as masseteric muscle spasm potentially heralding MH. This could account for the large number of patients referred for MH screening who are shown to have normal muscle. It is also quite likely that a proportion of these may release so much skeletal muscle myoglobin as to exhibit overt myoglobinuria, increased serum CK concentration and hyperkalaemia [8] . With these signs, it is not surprising that anaesthetists interpret them as heralding MH-yet the patient can be differentiated from the true MH reactor by demonstrating absence of hypermetabolism by measurement of blood-gas tensions and production of carbon dioxide, in addition to clinical monitoring of heart rate and body core temperature.
When patients are referred for MH screening following suxamethonium-induced masseteric spasm, it is unusual for the referring anaesthetist to comment on how long the abnormality lasted. This information might be important in distinguishing between normal subjects and those with muscle disease of MH. It is tempting to suggest that the longer the spasm lasts, the more likely it is for the patient to have abnormal muscle. Arbitrary limits have already been suggested [9] , although we believe the information must be collected prospectively to make possible an answer to this important question.
